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How Keratinocytes and Lymphocytes Interact 
Recently, B ri an Nickoloff and his colleagues at Stanford Uni-
versity Medical School discovered that the major histocompati-
bili ty antigen HLA-DR is induced on keratinocytes by y-inter-
feron. So Nickoloff, Teresa Basham, T homas Merigan, John 
Torseth, and Vera Morhenn decided to go on from there and 
furth er investigate the role of the skin in the functioning of the 
immune sys tem. T heir results, which they report in this issue, 
demonstrate that reactions between keratinocytes and lympho-
cytes are more complex than they and o thers envisioned. For 
example, keratinocytes may produce an important inhibitor of 
lymphocy te proliferation. 
Since y-interferon induces HLA-DR antigens on keratinocytes, 
Nickoloff and his associates began by asking: what are the im-
mediate consequences of these antigens in determining the inter-
actions between keratinocytes and lymphocytes? ' Normally , 
Nickoloff notes, keratinocytes do not exp ress HLA-DR an tigens, 
but they do express these antigens in a variety of skin diseases. 
It seemed poss~ble that expression of these histocompatibility an-
tigens may stimulate lymphocytes or otherwise enhance immune 
reactions. 
T he inves tigators began by incubating, in vitro, lymphocytes 
from one person with keratinocytes from another person. In one 
group of experiments, the keratinocytes were stimulated by y-
interferon so that they were expressing HLA-DR antigens and in 
another group of experiments they were not stimulated to express 
the antigens. 
Nickoloff and his colleagues found that the allogeneic lym-
phocytes increased thei r RNA synthesis and y-interferon pro-
du ction, indicating that the lymphocytes were ac tivated by the 
keratinocytes . The majority of these activated lymphocytes, how-
ever, did not divide . Keratinocytes, Nickoloff suggests, may 
produ ce soluble factors that inhibit lymphocyte proliferation in 
general, thereby preventing the activated lymphocytes from di-
viding. In addition, the lymphocytes may be inhibited from di-
viding in part because their IL-2 production is indirectly impaired 
by y-interferon . 
The investigators propose that there is a check and balance set 
of interactions, i. e., keratinocytes activate lymphocytes but they 
also may produce a factor to inhibit lymphocyte proliferation. At 
the sa me time, the stimulated lymphocytes produce y-interferon 
which, in turn, further stimulates the keratinocytes to express the 
HLA-DR antigen. The Stanford resea rchers are now tryin g to 
isolate the illhibitory factor produced by keratinocytes. 
The connection with herpes simplex lies in the fact that viral 
infection often occurs after sun exposure. The sunlight might 
modul ate the production of the lymphocyte suppressor by ke-
ratinocytes, Nickoloff proposes, and might thereby effect the 
form ation of a lesion . In fact, Y. Hayashi and L. Aurelian ofJohns 
Hopkins University Medical School reported in the February 1986 
issue of the Journal of Immunology that they have partially purified 
such an inhibitor of lymphocytes found in UVB-exposed mouse 
epiderm al cells that had been cultured with herpes simplex an-
tigen . 
The Stanford inves tigators conclude that the kera tinocytes with 
HLA-DR antigen do not interact with lymphocytes in the same 
way as do Langerhans cells with the HLA-DR antigen. The group 
now plans to measure the ability of keratinocytes with the HLA-
DR antigen to present herpes antigens to lymphocytes. One ques-
tion is whether the expression of the HLA-DR antigen targets 
keratinocytes for destruction by cytotoxic T cells. 
Inhibiting Benzo[a]Pyrene Activation With Clotrimazole 
Although imidazole compounds, such as clotrimazole, are used 
clinically as an tifungal agents, they have another, unrelated effect 
that may play an important role in chemica l carcinogenesis. These 
compounds inhibit the monooxygenase system of liver cells, an 
enzy me sys tem that converts polycyclic aromatic hydroca rbons 
into carcinogens. Mukul Das, Hasan Mukhtar, Benjamin DelTito, 
Cynthia Marcelo, an d David Bickers of the Veterans Adminis-
tration Medica l Center in C leveland reasoned that clo trimazole 
might also inhibit the monooxygenase system of skin cells, thereby 
provid ing a way to protect skin from polycyclic aro matic hy-
drocarbons. They report their res ults in this issue. 
When the aro matic hydrocarbon benzo[a]pyrene enters skin 
cells , it is converted by the cells' monooxygenase sys tem to me-
tabolites that bind to DNA and induce mutations in the cells. The 
DNA binding by these metabolites is thought to be an initial step 
in carcinogenesis. 
To determine whether or not clotrimazole prevents the acti-
vation of benzo[a]pyrene by the monooxygenase system into a 
carcinogen, Bickers and his colleagues used cultured mouse ke-
ratinocytes and found that it did. 
The significance of this finding , says Bickers, is that "we have 
identified a relatively nontoxic substance with anticarcinogenic 
effects. " The finding might prove clinically useful, he speculates , 
because workers who are exposed to aromatic hydrocarbons have 
an increased incidence of skin cancer. Imidazoles, such as clotri-
mazole, might help lower their cancer risk by inhibiting this 
production of chemical carcinogens. 
Tying Proteolysis to Psoriasis 
In the 1950s, it was suggested that involved psoriatic skin had 
more active protease(s) activity than unin volved psoriatic skin or 
skin from people who did not have psoriasis . Then, last year, 
Madalene Heng and her colleagues at the Veterans Administration 
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Medical Center in Sepulveda, California, reported that psoriasis 
patients with severe disease tend to have ai-antitrypsin activity, 
an enzyme that inhibits some proteolytic enzymes. If psoriatic 
patients have both increased proteolytic ac tivity and defective 
inhibitors of these enzymes, they might be expected to have more 
severe psoriasis, Heng reasoned . 
So H eng and her colleague Suni Kloss decided to investiga te 
the relation between ai-antitrypsin activity and psoriasis by elec-
tron microscopy. They report their results in this issue. 
The researchers noti ced previously that, 2 minutes after tape-
stripping skin of psoriasis patients , electron lucent defects in the 
basal lamina are observed within the epidermis and dermis that 
may be due to release of activated proteases . Heng and Kloss next 
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decided to determine whether psoriasis patients with an inherited 
deficiency of ai-antitrypsin, either the Z or the S variant, had 
more or larger electron lucent defects following tape-stripping . 
They observed that the electron lucent defects in the basement 
membranes of patients wi th inherited deficiencies of ai-antitryp-
sin were substantially larger than those in psoriatic patients with 
normal ai-antitrypsin activity. This finding is consistent with 
their original hypothesis. Moreover, patients with the Z variant 
which is less active than the S variant of ai -antitrypsin, had the 
larges t defects in their basement membranes. These findings, says 
Heng, "support the hypothesis that proteolytic enzymes are im-
portant in the pathogenesis and clinical severity of psorias is." 
Fibronectin Synthesis by Epithelial Cells 
Richard Clark and his colleagues at the N ational Jewish Center 
in Denver wondered what cells produced the fibronectin that 
appears during wound healing, inflammation , embryogenesis, 
and the growth of epithelial tumors . One possibility is that fi-
bronectin comes from the plas ma , and plasma does appear to be 
an initial source of the protein during wound repair. But later in 
the process of reepithelialization, fibronectin seems to be made 
in situ. In this issue, Clark, Ronald Grimwood, C harles Ferris, 
Larry Nielson, and J. Clark Huff report that fibronectin is syn-
thesized in vivo by epithelial cells. 
The importance of fibron ectin, C lark notes, res ts in the fac t 
that it is found in areas where there is extensive cell movement 
and proliferation . In addition, fibronectin enhances cell move-
ment, cell adhesion, and cell migra tion in in vitro assays. 
During wound healing, fibronectin appears to be synthesized 
by the prolifera tin g cells. Yet it was unclea r whether the protein 
was made by the overlying epidermal cells or by the underlying 
fibroblasts. " Fibroblasts in tissue culture make lo ts of fibronectin, 
so our first assu mption was that it was made by fibroblasts. But 
there was no definite method to use in the wound healing model 
to prove this assumption," says Clark. 
The in ves tigators decided to use an in vivo transplanted tumor 
model. They developed species-specific antifibronectin antibodies 
and used them to determine whether the fibronectin produced by 
human basal cell carcinomas transplanted into nude mice was of 
human or mouse origin. In this model the immunoreactive fi-
bronectin was of human origin, indicating that the human epi-
thelial cells synthesized fibronectin in vivo. 
These results raise immediate questions about fibron ectin that 
are of both clinical and theoretical interest, says Clark. For ex-
ample, if fibronectin synthesis is inhibited by epithelial cell tu-
mors, would that stop tumor growth? Conversely, if fibronectin 
synthesis is increased in migrating epithelial cells, would that 
enhance reepithelialization? These and other questions about the 
role of fibron ectin can now be more easily investigated. 
